

## **Remarks**

The application has been amended to add SEQ ID NO's. to the brief descriptions of the drawings for figures 4 and 5 as requested by the Examiner.

A complete listing of the claims, in ascending numerical order, is presented beginning on page 3 of this response. Claims 30, 32-41 and 73, 74, 76, and 77 remain in this application. Claims 35-37 have been amended to correct a formatting error that substituted "a" for the Greek letter "α" Claim 37 has also been amended to correct a typographical error in the term "Gpa1" that had been introduced during prosecution. Thus claims 35-37 are now as originally presented in this application. Claims 73, 74, 76, and 77 have been amended to depend directly on claim 30, and in the case of claims 74 and 77, to replace the term "an" with "the", as suggested by the Examiner. Support for these amendments can be found in their specification and claims as originally filed, at for example pages 101-102 and 121. Without conceding the Examiner's position or relinquishing their right to pursue patent protection for any cancelled subject matter, applicants have cancelled Claims 72, 75 and 78 in order to put the application in better condition for allowance. Claims 30, 32-34 and 38-41 are as previously or originally presented.

Claims 72, 74, 75, 77 and 78 were rejected by the Examiner under USC 112. In response, applicants have cancelled claims 72, 75 and 78, and have amended claims 74 and 77 as suggested by the Examiner.

Claims 73 and 76 were objected to by the Examiner as being dependent on a rejected base claim. In response, applicants have amended claims 73 and 76 to remove dependency on the rejected claims, as suggested by the Examiner.

Claims 35-37 were objected to by the Examiner due to informalities. In response, applicants have amended these claims as indicated above to remove the informalities.

The above amendments do not involve any issue of new matter. Therefore, the entry of these amendments is respectfully requested.

Accordingly, in view of the amendments set forth above, applicants respectfully submit that all claim objections and claim rejections under 35 USC 112 as described in the above-mentioned Office Action have been overcome and request their withdrawal. Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Agent for Applicants can be reached at the telephone number and address below.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'AAS Stewart', with a horizontal line extending from the end of the signature.

Alexander A. Stewart, Ph.D.  
Agent for Applicants  
Registration No. 47,110  
Telephone No. (631) 962-2149  
Fax No. (631) 752-3880

July 13, 2006  
OSI Pharmaceuticals, Inc.  
41 Pinelawn Road  
Melville, NY 11747